Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
There is likely a role for using anti-fibrotic medications in patients with
myositis-associated interstitial lung disease (MA-ILD) to slow down disease progression,
especially in patients who have fibrotic and progressive disease. These patients however are
currently being excluded from clinical trials of anti-fibrotic agents in progressive ILD
because of the concomitant use of immunosuppression. The benefit of anti-fibrotic agents is
being assessed in other rheumatic diseases and should be assessed in MA-ILD as well. They are
a unique group of patients with a heterogeneous disease, and are much more frequently on
concomitant immune-modulating therapy. As such, they should be studied on their own in
separate clinical trials, and the use of nintedanib should be studied as an addition to
standard of care immunosuppression.
The objective of this study is to assess safety and tolerability of nintedanib in patients
with MA-ILD.
Phase:
N/A
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre